Market Overview - The animal health sector experienced a decline of 1.01% on August 28, with *ST Lvkang leading the drop [1] - The Shanghai Composite Index closed at 3843.6, up 1.14%, while the Shenzhen Component Index closed at 12571.37, up 2.25% [1] Stock Performance - Notable gainers included: - Qudongli (838275) with a closing price of 11.07, up 5.23% [1] - Xianfeng Holdings (002141) at 4.19, up 1.21% [1] - Zhongmu Co. (600195) at 7.63, up 0.66% [1] - Major decliners included: - *ST Lvkang (002868) at 27.20, down 3.51% [2] - Shenyuan Bio (688098) at 12.59, down 2.70% [2] - KQ Bio (688526) at 18.40, down 1.55% [2] Capital Flow - The animal health sector saw a net outflow of 136 million yuan from institutional investors, while retail investors contributed a net inflow of 101 million yuan [2] - The detailed capital flow for key stocks showed: - Zhongmu Co. had a net outflow of 18.59 million yuan from institutional investors [3] - *ST Lvkang experienced a significant net outflow of 7.31 million yuan from institutional investors [3] - Retail investors showed a net inflow of 5.64 million yuan into *ST Lvkang [3]

Core Viewpoint - The approval of "Chlorhexidine Acetate Soft Capsules" as a new veterinary drug by the Ministry of Agriculture and Rural Affairs of the People's Republic of China marks a significant development for the company and the veterinary pharmaceutical industry [1] Company Summary - Wuhan Huisheng Biotechnology Co., Ltd. and its subsidiaries jointly applied for the new veterinary drug registration [1] - The new veterinary drug registration certificate was issued on August 26, 2025, under the announcement No. 943 by the Ministry of Agriculture and Rural Affairs [1] Industry Summary - The approved drug, Chlorhexidine Acetate Soft Capsules, is intended for use as a disinfectant and antiseptic [1] - It is specifically used to treat vaginal inflammation in pigs caused by sensitive bacteria, prevent postpartum uterine infections, and address endometritis caused by sensitive bacteria [1]

Core Viewpoint - The approval of "Chlorhexidine Acetate Soft Capsules" as a new veterinary drug by the Ministry of Agriculture and Rural Affairs of the People's Republic of China marks a significant development for the company and the veterinary pharmaceutical industry [1]. Company Summary - Wuhan Huisheng Biotechnology Co., Ltd. and its subsidiaries have jointly applied for the new veterinary drug, which has now received official registration [1]. - The new veterinary drug is aimed at treating conditions in pigs, specifically vaginitis caused by sensitive bacteria, and preventing postpartum uterine infections and endometritis [1]. Industry Summary - The approval of new veterinary drugs like Chlorhexidine Acetate Soft Capsules reflects ongoing advancements in the veterinary pharmaceutical sector, enhancing treatment options for livestock [1]. - The regulatory framework under which the drug was approved includes the "Veterinary Drug Management Regulations" and the "Veterinary Drug Registration Measures," indicating a structured approach to drug approval in the industry [1].

Market Overview - The animal health sector experienced a slight decline of 0.03% on August 26, with Shenlian Biological leading the drop [1] - The Shanghai Composite Index closed at 3868.38, down 0.39%, while the Shenzhen Component Index closed at 12473.17, up 0.26% [1] Stock Performance - Key stocks in the animal health sector showed varied performance: - KQ Bio (688526) rose by 6.80% to close at 19.33, with a trading volume of 167,100 shares and a turnover of 327 million yuan [1] - Huisheng Biological (300871) increased by 1.48% to 24.00, with a trading volume of 160,900 shares and a turnover of 387 million yuan [1] - Shenlian Biological (688098) fell by 8.41% to 13.28, with a trading volume of 313,100 shares and a turnover of 433 million yuan [2] Capital Flow - The animal health sector saw a net outflow of 68.22 million yuan from institutional investors, while retail investors had a net inflow of 76.14 million yuan [2][3] - Notable capital flows for specific stocks include: - Huisheng Biological had a net outflow of 56.08 million yuan from institutional investors [3] - Zhongmu Co. (600195) experienced a net inflow of 3.88 million yuan from institutional investors [3] - KQ Bio had a net outflow of 20.91 million yuan from institutional investors [3]

Market Overview - On August 25, the animal health sector rose by 1.47%, led by Shenlian Biological, while the Shanghai Composite Index closed at 3883.56, up 1.51%, and the Shenzhen Component Index closed at 12441.07, up 2.26% [1]. Stock Performance - Shenlian Biological (688088) closed at 14.50, with a significant increase of 13.81% and a trading volume of 521,000 shares, amounting to 723 million yuan [1]. - Other notable stocks included: - KQ Biological (688526) at 18.10, up 2.67% [1]. - Dayu Biological (871970) at 10.25, up 1.18% [1]. - Huisheng Biological (300871) at 23.75, up 0.93% [1]. - Ruip Biological (300119) at 23.48, up 0.86% [1]. - Jinhai Biological (002688) at 7.31, up 0.55% [1]. Capital Flow - The animal health sector experienced a net outflow of 40.13 million yuan from institutional investors, while retail investors saw a net outflow of 60.97 million yuan. Conversely, speculative funds had a net inflow of 101 million yuan [2]. Individual Stock Capital Flow - Shenlian Biological had a net inflow of 35.39 million yuan from institutional investors, while retail investors faced a net outflow of 74.83 million yuan [3]. - Other stocks with notable capital flows included: - Pulaike (603566) with a net inflow of 3.28 million yuan from institutional investors and a net outflow of 9.68 million yuan from retail investors [3]. - Huisheng Biological (300871) had a net inflow of 2.55 million yuan from institutional investors but a net outflow of 13.77 million yuan from retail investors [3].

Investment Rating - Industry rating: Outperform the market (maintained rating) [9] Core Insights - The pet industry is experiencing significant growth, with the Asia Pet Expo showcasing over 2,600 exhibitors and 20,000 brands, indicating a thriving market driven by globalization and innovation [2][13] - China's pet food exports have shown continuous growth, with 201,000 tons exported from January to July 2025, reflecting a year-on-year increase of 6.64% [14] - The pig farming sector is facing challenges, with the average pig price at 13.82 yuan/kg, a decrease of 3.63% from the previous week, and the average weight of pigs reaching a historical high [15][16] - The dairy sector is poised for a recovery, with the original milk price expected to rebound as production capacity decreases after a prolonged period of losses [17][18] - The poultry sector is focusing on breeding gaps, with a significant decline in the import of breeding chickens due to avian influenza concerns, which may impact future supply [19][20] - The planting sector emphasizes food security and the importance of biotechnology, with a focus on high-yield and resilient crop varieties [25] - The feed sector is recommended for investment, particularly in companies like Haida Group, which is expected to benefit from market recovery and increased market share [26] Summary by Sections Pet Sector - The Asia Pet Expo has reached a record scale of 310,000 square meters, highlighting the industry's vitality and innovation potential [2][13] - Pet food exports from China have increased, with a total of 201,000 tons exported in the first seven months of 2025, showing a year-on-year growth of 6.64% [14] - Recommended companies include pet food brands like Guibao Pet, Zhongchong Co., and Petty Co. [14] Pig Sector - The average pig price is currently at 13.82 yuan/kg, with a year-to-date low in profitability for pig farming [15][16] - The average weight of pigs is at a historical high, indicating supply pressures [15] - Recommended companies include leading pig farming firms such as Wens Foodstuffs Group and Muyuan Foods [16] Dairy Sector - Yuran Dairy reported stable performance with a revenue of 10.3 billion yuan, showing a year-on-year growth of 2.3% [17] - The dairy industry is expected to see a recovery as production capacity decreases [18] - Recommended companies include Yuran Dairy and China Shengmu Organic Milk [18] Poultry Sector - The poultry sector is facing challenges with breeding imports, particularly for white chickens, due to avian influenza [19][20] - Recommended companies include Shennong Development and Yisheng Livestock [20] Planting Sector - The focus is on food security and biotechnology, with an emphasis on high-yield and resilient crop varieties [25] - Recommended companies include Longping High-Tech and Dabeinong Technology Group [25] Feed Sector - Haida Group is highlighted as a key investment opportunity due to its increasing market share and performance [26] - The animal health sector is also recommended, particularly companies like Kexin Biological [27]

武汉回盛生物科技股份有限公司 章 程 （本章程经 2025 年第二次临时股东大会审议通过后生效） 二零二五年八月 | | | | | | 武汉回盛生物科技股份有限公司 章程 第一章 总则 第一条 为维护公司、股东和债权人的合法权益，规范公司的组织和行为，根据 《中华人民共和国公司法》（以下简称《公司法》）、《中华人民共和国证券法》 （以下简称《证券法》）、中国证券监督管理委员会（以下简称"中国证监会"） 颁布的《上市公司章程指引》和其他有关规定，制订本章程。 第二条 武汉回盛生物科技股份有限公司系依照《公司法》和其他有关规定成立 的股份有限公司（以下简称"公司"或"本公司"）。 公司是武汉回盛生物科技有限公司以整体变更的方式设立的股份公司；在湖北省 武汉市市场监督管理局注册登记，取得营业执照，统一社会信用代码： 9142011273354032X9。 第三条 公司于 2020 年 7 月 27 日经中国证券监督管理委员会注册，首次向社会 公众发行人民币普通股 2,770 万股，于 2020 年 8 月 24 日在深圳证券交易所上市。 第四条 公司注册名称：武汉回盛生物科技股份有限公司 英文名称：WUHAN H ...

证券代码：300871 证券简称：回盛生物 公告编号：2025-081 2025年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形； 2、本次股东大会未涉及变更以往股东大会已通过的决议； 3、本次股东大会审议的议案为特别决议事项，已经出席本次股东大会的 非关联股东（包括股东代理人）所持表决权的2/3以上通过。 一、会议召开和出席情况 （一）会议召开情况 1、会议召开时间： （1）现场会议召开时间：2025年8月22日（星期五）14:00 武汉回盛生物科技股份有限公司 6、会议召开的合法、合规性：本次股东大会会议的召开符合有关法律、 行政法规、部门规章、规范性文件、深交所业务规则和《公司章程》等规定。 （二）会议的出席情况 1、股东出席的总体情况 通过现场和网络投票的股东242人，代表股份94,220,423股，占公司有表决 权总股份的46.7412％。其中：通过现场投票的股东3人，代表股份93,276,163 股，占公司有表决权总股份的46.2728％；通过网络投票的股东239人，代表 ...

国浩律师（深圳）事务所 法律意见书 国浩律师（深圳）事务所 关于武汉回盛生物科技股份有限公司 2025年第二次临时股东大会法律意见书 致：武汉回盛生物科技股份有限公司 国浩律师（深圳）事务所（以下简称"本所"）接受武汉回盛生物科技股份 有限公司（以下简称"公司"）的委托，指派彭瑶律师、季俊宏律师（以下简称 "本所律师"）出席公司2025年第二次临时股东大会（以下简称"本次股东大会" 或"本次会议"），对本次股东大会的合法性进行见证。本所律师根据《中华人 民共和国公司法》（以下简称"《公司法》"）、《上市公司股东会规则》等法 律、法规和规范性文件以及《武汉回盛生物科技股份有限公司章程》（以下简称 "《公司章程》"）的规定，就公司本次股东大会的召集、召开程序、出席会议 人员的资格、召集人的资格、表决程序和表决结果等有关事宜出具本法律意见书。 在本法律意见书中，本所律师仅对本次股东大会的召集、召开程序、出席会 议人员资格、召集人的资格、表决程序以及表决结果是否符合相关法律、法规、 其他规范性文件及《公司章程》的规定发表意见，不对会议审议的议案内容以及 这些议案所表述的事实或数据的真实性及准确性发表意见。 按照律师行 ...

Market Overview - The animal health sector experienced a decline of 0.76% on August 22, with Yongshun Biological leading the drop [1] - The Shanghai Composite Index closed at 3825.76, up 1.45%, while the Shenzhen Component Index closed at 12166.06, up 2.07% [1] Individual Stock Performance - Yongshun Biological (code: 839729) closed at 11.18, down 4.36% with a trading volume of 91,600 shares and a turnover of 102 million yuan [1] - Dayu Biological (code: 871970) closed at 10.13, down 2.78% with a trading volume of 32,700 shares and a turnover of 33.49 million yuan [1] - Shunlian Biological (code: 688098) closed at 12.74, down 2.00% with a trading volume of 317,600 shares and a turnover of 412 million yuan [1] - Other notable declines include Xianfeng Holdings (code: 002141) down 1.79% and Jinhai Biological (code: 002688) down 1.36% [1] Capital Flow Analysis - The animal health sector saw a net outflow of 74.19 million yuan from institutional investors, while retail investors had a net inflow of 91.60 million yuan [1] - Key stocks with significant capital flow include: - Huisheng Biological (code: 300871) with a net outflow of 9.62 million yuan from institutional investors [2] - Kexin Biological (code: 688526) with a net inflow of 7.28 million yuan from institutional investors [2] - ST Lvkang (code: 002868) had a net outflow of 3.99 million yuan from institutional investors but a net inflow of 3.77 million yuan from retail investors [2]